C.R. Bard (BCR) : $17.41 million worth of transactions were on upticks in C.R. Bard (BCR), compared to $10.62 million on downticks. The ratio between the two was 1.64, whereas, the net money flow stood at a healthy $6.79 million on Fridays session. The consistent buying on upticks in the stock accounted for $5.38million worth of trades. The total money flow into the stock stood at $5.38 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.13%. The stock was trading at $221.21, with a drop of $0.29 over the previous days close. The stock recorded 1.91% for the week.
The company Insiders own 0.97% of C.R. Bard shares according to the proxy statements. Institutional Investors own 88.3% of C.R. Bard shares. During last six month period, the net percent change held by insiders has seen a change of -5.91%.
In a related news,The officer (Senior Vice President and CFO) of Bard C R Inc /Nj/, Holland Christopher S sold 3,970 shares at $219.88 on May 27, 2016. The Insider selling transaction had a total value worth of $872,924. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
C.R. Bard (NYSE:BCR): stock was range-bound between the intraday low of $220.37 and the intraday high of $222.6299 after having opened at $221.98 on Fridays session. The stock finally closed in the red at $221.98, a loss of -0.13%. The stock remained in the red for the whole trading day. The total traded volume was 229,391 shares. The stock failed to cross $222.6299 in Fridays trading. The stocks closing price on Thursday was $221.5.
C.R. Bard (BCR) has been under a strong bear grip, hence the stock is down -0.46% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.4% in the past 1 week. The stock has risen by 1.91% in the past week indicating that the buyers are active at lower levels, but the stock is down -0.59% in the past 4 weeks.
C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. The Companys vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs, in addition to hemostats and surgical sealants.